Showing results (71-80 of 89) with videos related to

Sort By:
Pageof 9
Medicina (Kaunas, Lithuania)|January 25, 2025
The Effect of Systemic Inflammation and Clinicopathologic Features on Survival in Malignant Pleural Mesothelioma: A Multicenter AnalysisNadiye Sever, Sedat Yıldırım, Ali Fuat Gurbuz, et al.
Annals of Saudi Medicine|August 3, 2025
Clinicopathological features and treatment outcomes of patients with fibrolamellar hepatocellular carcinoma: a retrospective multicenter studyAli Kaan Güren, Hilal Polat, Eyüp Çoban, et al.
Journal of Clinical Medicine|August 28, 2025
Comparison of Frontline FOLFIRINOX with Fluorouracil-Based and Gemcitabine-Based Chemotherapies in Metastatic Ampullary Adenocarcinoma: A Multicenter Study by the Turkish Oncology Group (TOG)Ali Kalem, Tulay Kus, Savas Gokcek, et al.
Journal of Chemotherapy (Florence, Italy)|June 21, 2024
Real-world data on the efficacy and safety of trastuzumab emtansine in patients with metastatic breast cancer previously treated with pertuzumab: Turkish oncology group multicenter studyÖzgecan Dülgar, Sema Türker, Gül Başaran, et al.
Cancers|September 13, 2025
FOLFIRINOX: The Best Adjuvant Treatment for Ampullary Adenocarcinoma? A Multicenter Study by the Turkish Oncology Group (TOG)Ali Kalem, Tulay Kus, Taha Koray Sahin, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|July 4, 2026
Efficacy and safety of second-line treatments in ALK mutation-positive advanced non-small cell lung cancer after second- or third-generation ALK inhibitors: Turkish Oncology Group real-life study (TOG study)Cihan Erol, Esra Zeynelgil, Mutlu Hizal, et al.
Journal of Geriatric Oncology|September 8, 2023
PROPSEA, safety evaluation of palbociclib and ribociclib in older patients with breast cancer: A prospective real-world TOG studyOkan Avcı, Yakup İriağaç, Eyyüp Çavdar, et al.
The Turkish Journal of Gastroenterology : the Official Journal of Turkish Society of Gastroenterology|April 17, 2025
Efficacy of Second-Line Treatments After Atezolizumab and Bevacizumab in Advanced Hepatocellular Carcinoma and Related Prognostic Factors: A Multicenter Study by the Turkish Oncology Group (TOG)Nargiz Majidova, Sendag Yaslıkaya, Maral Martin Mıldanoglu, et al.
Cancers|January 10, 2026
Durvalumab-Based First-Line Chemoimmunotherapy in Advanced Biliary Tract Cancer: Real-World Outcomes and Prognostic Factors-A Turkish Oncology Group StudySafa Can Efil, Fatih Kus, Bahadir Koylu, et al.
Journal of Clinical Medicine|June 26, 2025
Induction or Adjuvant Chemotherapy in Patients with Locally Advanced Nasopharyngeal Cancer Receiving Chemoradiotherapy? A Turkish Oncology Group StudySerhat Sekmek, Aysel Oguz, Melek Karakurt Eryilmaz, et al.
Pageof 9